PharVision Advisers’s eGain EGAN Stock Holding History

PharVision Advisers’s Portfolio EGAN Stock Details EGAN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,550	Closed	-$83.2K	–	81
2026 Q1	$83.2K	Sell	10,550 -8,825	-46%	-$85.2K	0.84%	61
2025 Q4	$199K	Buy	+19,375	New	+$232K	0.1%	562

Other funds holding EGAN

OCMI

Oaktop Capital Management II Chatham, New Jersey $2.35B AUM 214.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

PharVision Advisers's EGAN Position: Q2 2026 in Review

PharVision Advisers sold out of eGain (EGAN) in Q2 2026, closing a stake of 10,550 shares — an estimated $83.2K sold.

PharVision Advisers first reported a position in EGAN in Q4 2025 and held it in 2 quarters. The position peaked at $199K in Q4 2025. 105 funds tracked by Wall St. Rank hold EGAN as of Q2 2026.

PharVision Advisers reported no remaining eGain position as of Q2 2026 after selling out during the quarter.
PharVision Advisers sold 10,550 eGain shares in Q2 2026, an estimated $83.2K.
PharVision Advisers first reported a position in eGain in Q4 2025 and held it in 2 quarters.
PharVision Advisers's eGain position peaked at $199K in Q4 2025.
105 funds tracked by Wall St. Rank held eGain as of Q2 2026.

Based on PharVision Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.